Patents Represented by Attorney Andrea V. Lockenour
  • Patent number: 8314232
    Abstract: The present invention relates to a process of preparing a compound of the following formula III: wherein R1-R4 are as defined herein. The present invention also relates to the preparation of intermediates used to prepare the compound of formula III.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: November 20, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicole Marie Deschamps, Michael Tolar Martin, Michael John Monteith, Xiaoming Zhou
  • Patent number: 8114845
    Abstract: Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 14, 2012
    Assignee: Amplimmune, Inc.
    Inventors: Solomon Langermann, Linda Liu
  • Patent number: 7622302
    Abstract: New processes for improving the manufacture of clavams e.g. clavulanic acid. Novel DNA sequences and new microorganisms capable of producing increased amounts of clavulanic acid are also disclosed.
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: November 24, 2009
    Assignees: Glaxo Group Limited, The Governors of the University of Alberta
    Inventors: Barry Barton, Alison Michelle Griffin, Susan Jensen, Annie Wong
  • Patent number: 7531316
    Abstract: This invention relates to a method for determining the activity of Lp-PLA2 in a plurality of samples from animals. The invention also relates to a kit for determining Lp-PLA2 activity in a plurality of samples.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: May 12, 2009
    Assignee: Glaxo Group Limited
    Inventors: Yun-Fu Hu, George T. Walker
  • Patent number: 7504102
    Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 17, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
  • Patent number: 7399837
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 15, 2008
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Patent number: 7344869
    Abstract: Novel bacterial genes, microorganisms and processes for improving the manufacture of 5R clavams, eg. clavulanic acid.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: March 18, 2008
    Assignees: SmithKline Beecham p.l.c., The Governors of the University of Alberta
    Inventors: Cecilia Anders, Barry Barton, John Patrick Griffin, Susan Jensen, Roy Henry Mosher, Ashish Sudhakar Paradkar
  • Patent number: 7314742
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: January 1, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Patent number: 7291332
    Abstract: The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory arthropathy or inflammatory disorder, and the use of OSM in screening for such antagonists.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: November 6, 2007
    Assignee: SmithKline Beecham Corporation
    Inventor: Paul F. Life
  • Patent number: 7230083
    Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: June 12, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
  • Patent number: 7109233
    Abstract: This invention relates in general to certain substituted substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamides of formula I as defined herein which are protease inhibitors.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: September 19, 2006
    Assignee: SMithKline Beecham Corporation
    Inventors: Jae U. Jeong, Dennis S. Yamashita
  • Patent number: 7087405
    Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human ?v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: August 8, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Kyung O Johanson, Zdenka Ludmila Jonak, Alexander Taylor, Stephen H Trulli
  • Patent number: 7045329
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: May 16, 2006
    Assignee: SmithKline Beecham plc
    Inventors: Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Patent number: 7019008
    Abstract: A compound of Formula (I): wherein: R1 is C1-6 alkyl, benzyl, or (CH2)n—C(O)NH2; wherein the benzyl may be unsubstituted or substituted by one or two C1-6 alkyl, halogen, C1-6 alkoxy, or methylenedioxy groups; R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, C1-3 alkyl, C1-3 alkoxy, or methylenedioxy groups; X1 and X2 are independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy, nitro, CF3, or CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: March 28, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Steven D. Knight, Jian Jin, Ralph A. Rivero, Anthony Sapienza
  • Patent number: 6964865
    Abstract: DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin ?-lactams and such enzymes are expressed by hosts into which the recombinant vectors are transformed. The DNA and the enzymes encoded thereby have utility in the preparation of penicillins and cephalosporins, both known and novel, possessing pharmacological, especially antimicrobial, activity.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: November 15, 2005
    Assignee: Beecham Group plc
    Inventors: Martin Karl Russel Burnham, Ian David Normansell, John Edward Hodgson
  • Patent number: 6946130
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 20, 2005
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Patent number: RE40070
    Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.The questions raised in reexamination request, 09/006,966 filed Mar. 12, 2004 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: February 19, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Paula Shadle, John C. Erickson, Robert G. Scott, Thomas M. Smith
  • Patent number: RE40988
    Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: November 17, 2009
    Assignees: SmithKline Beecham Corporation, University of Texas Southwestern Medical Center at Dallas
    Inventors: Derk J. Bergsma, Masahi Yanigasawa
  • Patent number: RE41555
    Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecular proteins.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: August 24, 2010
    Assignee: Glaxosmithkline LLC
    Inventors: Paula Shadle, John C. Erickson, Robert G. Scott, Thomas M. Smith
  • Patent number: RE41595
    Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 31, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Paul J. Shandle, John C. Erickson, Robert G. Scott, Thomas M. Smith